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See related article by Jacob et al., http://ccforum.com/content/18/6/656Whether hydroxyethyl starch (HES) is safe for peri-
operative use is not known. Evaluating HES in cardiac
surgery, Jacob and colleagues suggested conclusion was
of a more favorable safety profile for HES 130/0.4 [1].
The authors, however, wrongly stated that they followed
the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) guidelines because the
meta-analysis lacked a table of included study character-
istics, an assessment of bias, identification of any pre-
specified subgroup analyses, and tests of interaction to
compare different HES solutions. In many included
studies, the control group received HES, patients with
heavy bleeding were excluded post hoc, and anti-
fibrinolytic drugs were used to minimize bleeding. For
instance, in two included trials the group assigned to
gelatin actually received significantly more postoperative
HES 130/0.4 than the group allocated to HES 130/0.4
[2,3]. In an included trial of HES 130/0.4, the results
from one of the four study centers were excluded post
hoc without explanation [4]. Other sources of bias were
aggregation of intra- with postoperative blood loss and
preferential use of calculated rather than measured
blood loss. Furthermore, no tests of interaction were
presented even to address the question of whether HES
130/0.4 differs from other HES solutions in its effect on
bleeding risk after cardiac surgery.
Between-study heterogeneity was shown to considerably
affect the use of meta-analyses for drug-safety alert issues
[5]. Even though meta-analyses may help predict iatro-
genic risks, in the field of perioperative volume resuscita-
tion with HES quality of meta-analytic evidence is still too
poor to reliably inform drug-regulatory authorities. ThisCorrespondence: christian.wiedermann@asbz.it
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